Rexahn Pharmaceuticals (RNN) Given a $20.00 Price Target by HC Wainwright Analysts

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) received a $20.00 target price from research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the stock.

A number of other analysts have also commented on the company. B. Riley set a $8.00 price objective on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 13th. Zacks Investment Research raised Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a report on Friday, August 10th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $10.69.

Shares of Rexahn Pharmaceuticals stock opened at $1.85 on Tuesday. Rexahn Pharmaceuticals has a one year low of $1.23 and a one year high of $3.19.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last issued its earnings results on Monday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03.

A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Northern Trust Corp boosted its position in Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 61.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 77,213 shares of the company’s stock after purchasing an additional 29,354 shares during the period. Northern Trust Corp owned about 0.24% of Rexahn Pharmaceuticals worth $117,000 as of its most recent SEC filing.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

See Also: Moving Average (MA)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply